Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 20 studies | 45% ± 13% | |
| brain | 18 studies | 38% ± 17% | |
| peripheral blood | 17 studies | 39% ± 12% | |
| intestine | 11 studies | 34% ± 15% | |
| kidney | 9 studies | 36% ± 10% | |
| eye | 9 studies | 37% ± 15% | |
| liver | 6 studies | 38% ± 20% | |
| heart | 5 studies | 26% ± 5% | |
| uterus | 5 studies | 49% ± 18% | |
| adipose | 5 studies | 26% ± 7% | |
| prostate | 5 studies | 37% ± 15% | |
| lymph node | 5 studies | 41% ± 12% | |
| pancreas | 4 studies | 66% ± 13% | |
| placenta | 4 studies | 49% ± 20% | |
| bone marrow | 4 studies | 30% ± 11% | |
| esophagus | 4 studies | 39% ± 27% | |
| skin | 4 studies | 34% ± 18% | |
| breast | 4 studies | 50% ± 9% | |
| adrenal gland | 3 studies | 27% ± 4% | |
| thymus | 3 studies | 52% ± 26% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 7798.28 | 459 / 459 | 100% | 53.22 | 1118 / 1118 |
| esophagus | 100% | 9168.83 | 1445 / 1445 | 100% | 45.50 | 183 / 183 |
| lung | 100% | 9842.71 | 578 / 578 | 100% | 51.42 | 1155 / 1155 |
| ovary | 100% | 10719.94 | 180 / 180 | 100% | 36.19 | 430 / 430 |
| uterus | 100% | 7481.46 | 170 / 170 | 100% | 50.80 | 459 / 459 |
| brain | 100% | 8481.24 | 2641 / 2642 | 100% | 58.71 | 705 / 705 |
| prostate | 100% | 6962.70 | 245 / 245 | 100% | 41.54 | 501 / 502 |
| kidney | 100% | 6693.62 | 89 / 89 | 100% | 34.57 | 899 / 901 |
| liver | 100% | 3872.27 | 226 / 226 | 100% | 26.73 | 405 / 406 |
| pancreas | 100% | 4995.40 | 327 / 328 | 100% | 41.29 | 178 / 178 |
| thymus | 100% | 6992.74 | 653 / 653 | 100% | 50.48 | 603 / 605 |
| bladder | 100% | 8570.86 | 21 / 21 | 100% | 42.84 | 502 / 504 |
| intestine | 100% | 9124.01 | 966 / 966 | 99% | 33.26 | 524 / 527 |
| skin | 100% | 8324.96 | 1809 / 1809 | 99% | 33.69 | 469 / 472 |
| stomach | 100% | 7290.26 | 359 / 359 | 99% | 33.67 | 284 / 286 |
| adrenal gland | 100% | 15968.51 | 258 / 258 | 99% | 41.60 | 228 / 230 |
| adipose | 100% | 7944.15 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 9804.02 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 31.18 | 29 / 29 |
| muscle | 100% | 8447.49 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 6682.86 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 44.90 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 15.80 | 1 / 1 |
| peripheral blood | 99% | 9036.23 | 917 / 929 | 0% | 0 | 0 / 0 |
| heart | 97% | 6208.82 | 833 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 95% | 21.81 | 76 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006686 | Biological process | sphingomyelin biosynthetic process |
| GO_0015914 | Biological process | phospholipid transport |
| GO_0015918 | Biological process | sterol transport |
| GO_0090114 | Biological process | COPII-coated vesicle budding |
| GO_0031175 | Biological process | neuron projection development |
| GO_0044829 | Biological process | positive regulation by host of viral genome replication |
| GO_0007029 | Biological process | endoplasmic reticulum organization |
| GO_0061025 | Biological process | membrane fusion |
| GO_0061817 | Biological process | endoplasmic reticulum-plasma membrane tethering |
| GO_0035627 | Biological process | ceramide transport |
| GO_0044828 | Biological process | negative regulation by host of viral genome replication |
| GO_0070972 | Biological process | protein localization to endoplasmic reticulum |
| GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
| GO_0034975 | Biological process | protein folding in endoplasmic reticulum |
| GO_0019076 | Biological process | viral release from host cell |
| GO_0006888 | Biological process | endoplasmic reticulum to Golgi vesicle-mediated transport |
| GO_0030301 | Biological process | cholesterol transport |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0048471 | Cellular component | perinuclear region of cytoplasm |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0035577 | Cellular component | azurophil granule membrane |
| GO_0070971 | Cellular component | endoplasmic reticulum exit site |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005829 | Cellular component | cytosol |
| GO_0015630 | Cellular component | microtubule cytoskeleton |
| GO_0005923 | Cellular component | bicellular tight junction |
| GO_0031965 | Cellular component | nuclear membrane |
| GO_0031982 | Cellular component | vesicle |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0019904 | Molecular function | protein domain specific binding |
| GO_0045296 | Molecular function | cadherin binding |
| GO_0033149 | Molecular function | FFAT motif binding |
| GO_0008017 | Molecular function | microtubule binding |
| GO_0046982 | Molecular function | protein heterodimerization activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | VAPA |
| Protein name | VAMP associated protein A Vesicle-associated membrane protein-associated protein A (VAMP-A) (VAMP-associated protein A) (VAP-A) (33 kDa VAMP-associated protein) (VAP-33) |
| Synonyms | VAP33 |
| Description | FUNCTION: Endoplasmic reticulum (ER)-anchored protein that mediates the formation of contact sites between the ER and endosomes via interaction with FFAT motif-containing proteins such as STARD3 or WDR44 . STARD3-VAPA interaction enables cholesterol transfer from the ER to endosomes . Via interaction with WDR44 participates in neosynthesized protein export . In addition, recruited to the plasma membrane through OSBPL3 binding . The OSBPL3-VAPA complex stimulates RRAS signaling which in turn attenuates integrin beta-1 (ITGB1) activation at the cell surface . With OSBPL3, may regulate ER morphology . May play a role in vesicle trafficking . . |
| Accessions | ENST00000400000.7 [Q9P0L0-1] ENST00000585042.5 J3QKM9 ENST00000340541.4 [Q9P0L0-2] Q9P0L0 |